2026-06-29T02:32:00Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1011952025-03-18T13:47:18Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Belli, Simone author Pacciardi, Bruno author Cotugno, B. author Cargioli, C. author Augusto, S. author Di Fiorino, A. author Mauri, M. author 2013 Introduction Weight gain is a common problem during antidepressant treatment, an important factor contributing to noncompliance, and a key issue influencing obesity-related illnesses. Selective serotonin reuptake inhibitors (SSRIs) seem to differ in terms of their effects on body weight, but the available literature on this topic is sparse, contradictory and lacking of data about new generation SSRIs. Methods This work evaluated clinical improvement and weight changes during the first three months of escitalopram treatment in 34 outpatients affected with depression and comorbid anxiety, assessed in a naturalistic follow-up. Outcome measures were weight change and clinical improvement assessed with CGI. Results After the first three months of therapy, there was a slight decrease in average body weight compared to baseline. However, the weight loss at three months did not reach statistical significance. Response to treatment was demonstrated by a statistically significant reduction in CGI score. Limitations Both the small sample size and short follow-up times limit our results. Other variables such as depressive severity, atypical features and premorbid weight should be taken into account during further follow-up. Conclusions Our preliminary data suggest that escitalopram may not be involved in weight gain, and confirm the efficacy of escitalopram treatment for depression with comorbid anxiety. 1592-1107 https://hdl.handle.net/20.500.14352/101195 https://old.jpsychopathol.it/wp-content/uploads/2015/07/08Pacciardi1.pdf Trattamento con escitalopram e peso corporeo : dati preliminari